|
|
Volumn 98, Issue 4, 2006, Pages 232-234
|
|
Criticism of tumor response criteria raises trial design questions.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
TUMOR MARKER;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DISEASE COURSE;
DISEASE FREE SURVIVAL;
DRUG SCREENING;
HUMAN;
METABOLISM;
METHODOLOGY;
NEOPLASM;
NOTE;
PATHOLOGY;
PHASE 2 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
REPRODUCIBILITY;
STANDARD;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE II;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
DRUG EVALUATION;
HUMANS;
NEOPLASMS;
RANDOMIZED CONTROLLED TRIALS;
REPRODUCIBILITY OF RESULTS;
RESEARCH DESIGN;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 33644859182
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djj086 Document Type: Note |
|
Times cited : (12)
|
|
References (0)
|
